Bill > HB1118

This bill creates new provisions to support the coverage and accessibility of abuse-deterrent opioid analgesic drug products in Missouri's healthcare system. Specifically, the bill requires insurance carriers and health plans to include at least one abuse-deterrent opioid analgesic drug product on their formularies for each active ingredient. An "abuse-deterrent opioid analgesic drug product" is defined as a medication approved by the FDA with labeling that indicates its ability to deter or reduce potential abuse. The bill mandates that cost-sharing for these abuse-deterrent products cannot exceed the lowest cost-sharing levels applied to non-abuse deterrent opioid drugs in the same category (brand name or generic). Furthermore, the legislation prohibits insurance providers from implementing additional patient cost-sharing or creating disincentives for prescribers to achieve compliance. The bill also stipulates that prior authorization requirements for opioid analgesics cannot require patients to first use non-abuse deterrent products before accessing abuse-deterrent alternatives, effectively ensuring easier access to these safer medication options. This legislation aims to encourage the use of opioid medications with built-in abuse prevention mechanisms, potentially helping to address opioid misuse and addiction issues.

Business and Industry

https://house.mo.gov/Bill.aspx?bill=HB1118&year=2025&code=R